Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update (article)

cites work (P2860)

Q39292642	'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study
Q38821174	(18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer
Q30315970	14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
Q39272681	18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer
Q52600754	3D Imaging Detection of HER2 Based in the Use of Novel Affibody-Quantum Dots Probes and Ratiometric Analysis.
Q92614334	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Q55000437	64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.
Q56516407	68Ga-NOTA-RM26 PET/CT in the Evaluation of Breast Cancer: A Pilot Prospective Study
Q50223041	89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Q90602596	89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
Q37414060	A Comparative Performance Analysis of Multispectral and RGB Imaging on HER2 Status Evaluation for the Prediction of Breast Cancer Prognosis
Q36206190	A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation
Q55322794	A New Paradigm for Tissue Diagnostics: Tools and Techniques to Standardize Tissue Collection, Transport, and Fixation.
Q54968815	A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer.
Q47577143	A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Q58423595	A Practical Approach to the Use of Immunohistochemistry in the Diagnosis and Management of Breast Disease
Q92140376	A Rare Case of Triple Positive Metachronous Breast Cancer
Q38641520	A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer
Q61448675	A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2 breast cancer
Q36860111	A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression
Q52680181	A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Q90589232	A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of ≥2.0 but an average HER2 copy number of <4.0 signals per cell
Q33639763	A critical analysis of cancer biobank practices in relation to biospecimen quality
Q36277170	A cut-off of 2150 cytokeratin 19 mRNA copy number in sentinel lymph node may be a powerful predictor of non-sentinel lymph node status in breast cancer patients
Q90352722	A decision tree-based prediction model for fluorescence in situ hybridization HER2 gene status in HER2 immunohistochemistry-2+ breast cancers: a 2538-case multicenter study on consecutive surgical specimens
Q35906737	A favourable prognostic marker for EGFR mutant non-small cell lung cancer: immunohistochemical analysis of MUC5B.
Q47107430	A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
Q35863010	A formalin-free method for stabilizing cells for nucleic acid amplification, hybridization and next-generation sequencing
Q64264734	A model for the impact of FFPE section thickness on gene copy number measurement by FISH
Q40978920	A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer
Q104471916	A negative binomial regression model for risk estimation of 0-2 axillary lymph node metastases in breast cancer patients
Q38760747	A new look at the ALK gene in cancer: copy number gain and amplification
Q47675278	A new molecular-based lymph node staging classification determines the prognosis of breast cancer patients
Q47127531	A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry
Q55065689	A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score.
Q60044022	A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study
Q88055520	A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity
Q42457595	A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma
Q88657584	A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients
Q51371303	A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2.
Q92100542	A novel role of kynureninase in the growth control of breast cancer cells and its relationships with breast cancer
Q41173029	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
Q38648408	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
Q89284730	A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study
Q86838793	A preliminary investigation of the role of the transcription co-activators YAP/TAZ of the Hippo signalling pathway in canine and feline mammary tumours
Q37341891	A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
Q36152629	A qualitative study comparing the assay performance characteristics between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 scoring methods in mucinous epithelial ovarian cancer
Q51697298	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Q92741938	A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
Q93060699	A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Q41662372	A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer
Q38929949	A review of consent practices and perspectives for pharmacogenetic testing
Q96431012	A self-sustaining endocytic-based loop promotes breast cancer plasticity leading to aggressiveness and pro-metastatic behavior
Q50990265	A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
Q47146801	A tissue microRNA signature that predicts the prognosis of breast cancer in young women
Q37085887	ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer
Q34042627	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.
Q92257886	APOBEC3B Gene Expression in Ductal Carcinoma In Situ and Synchronous Invasive Breast Cancer
Q38374808	ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis
Q49721138	Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers
Q92639181	Accelerated Tissue Processing With Minimal Formalin Fixation Time for 9-Gauge Vacuum-Assisted Breast Biopsy Specimens
Q54311896	Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations.
Q36614803	Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype
Q34231928	Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry
Q96305440	Actionable gene alterations in an Asian population with triple-negative breast cancer
Q33608593	Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes
Q47813594	Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
Q52675952	Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Q52691510	Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles.
Q38842844	Adipocytes can induce epithelial-mesenchymal transition in breast cancer cells.
Q47313470	Adiposity, Inflammation and Breast Cancer Pathogenesis in Asian Women.
Q38743961	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Q91738536	Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis
Q39018742	Adjuvant trastuzumab: a 10-year overview of its benefit.
Q90024930	Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
Q55105639	Advances in the systemic treatment of triple-negative breast cancer.
Q38612634	Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens
Q38980293	Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers
Q39863683	Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
Q90307333	Affibody Molecules as Targeting Vectors for PET Imaging
Q50609680	Agreement of Different Methods for Tissue Based Detection of HER2 Signal in Invasive Breast Cancer.
Q36546821	Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration
Q35538100	Altered PPP2R2A and Cyclin D1 expression defines a subgroup of aggressive luminal-like breast cancer.
Q37392829	Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer
Q41564734	Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer
Q38654175	Amplification and overexpression of PSCA at 8q24 in invasive micropapillary carcinoma of breast
Q37606324	Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer
Q53067561	An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes.
Q39037175	An international study to increase concordance in Ki67 scoring
Q40417660	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors
Q40466552	An optimized image analysis algorithm for detecting nuclear signals in digital whole slides for histopathology.
Q90608713	Analysis Natrium Iodide Symporter Expression in Breast Cancer Subtypes for Radioiodine Therapy Response
Q92860600	Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival
Q64238242	Analysis of Hormone Receptor Status in Primary and Recurrent Breast Cancer Via Data Mining Pathology Reports
Q38677201	Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer
Q92085817	Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study
Q39369156	Analytic inquiry: Validation and practical considerations.
Q41498719	Ancestry as a potential modifier of gene expression in breast tumors from Colombian women.
Q38552128	Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Q55709334	Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
Q37542959	Androgen Receptor Expression in Breast Carcinoma of Egyptian Patients
Q57298998	Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations
Q48201952	Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy
Q92331171	Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer
Q40828085	Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer
Q42366191	Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
Q54328011	Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Q52627339	Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
Q35088745	Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options
Q41092731	Androgen receptor status predicts development of brain metastases in ovarian cancers.
Q35631966	Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays
Q51310879	Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer.
Q36021686	Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype
Q43276367	Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast.
Q36834535	Application of multispectral imaging in quantitative immunohistochemistry study of breast cancer: a comparative study
Q55032245	Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.
Q91637171	Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different?
Q37220987	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?
Q36307517	Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.
Q64895271	Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer.
Q39263199	Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany
Q34511787	Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer
Q91845207	Assessment of ERBB2 and TOP2α gene status and expression profile in feline mammary tumors: findings and guidelines
Q90303216	Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
Q47700657	Assessment of HER-2 status in invasive breast cancer in Brazil.
Q35841024	Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method
Q54256014	Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
Q34446385	Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
Q36194523	Assessment of Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status in Breast Carcinoma Using Thin-Prep Cytology Fine Needle Aspiration Cytology FISH Experience From China
Q64114958	Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry
Q38384113	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Q41729795	Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines
Q88622458	Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease
Q38779230	Association Between Benign Breast Disease in African American and White American Women and Subsequent Triple-Negative Breast Cancer
Q55365832	Association between Changes in Serum 25-Hydroxyvitamin D Levels and Survival in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy.
Q45071124	Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Q55025169	Association of APEX1 and OGG1 gene polymorphisms with breast cancer risk among Han women in the Gansu Province of China.
Q42492427	Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3+ Tregs.
Q99583844	Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
Q38400780	Association of preoperative breast MRI features with locoregional recurrence after breast conservation therapy
Q35944405	Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study
Q91570513	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Q38656185	Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue
Q36304131	Automated fluorescent miscroscopic image analysis of PTBP1 expression in glioma
Q54344831	Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
Q90643971	Axillary Pathologic Complete Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer Patients: A Predictive Model Integrating the Imaging Characteristics of Ultrasound Restaging with Known Clinicopathologic Characteristics
Q33728272	BI-RADS 3-5 microcalcifications: prediction of lymph node metastasis of breast cancer
Q47769924	BRCA mutations in women with inflammatory breast cancer
Q50108671	BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Q36224769	BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
Q53627332	Bcl2 and Ki67 refine prognostication in luminal breast cancers.
Q36859845	Being Overweight or Obese Increases the Risk of Progression in Triple-Negative Breast Cancer after Surgical Resection.
Q53509601	Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer.
Q38933076	Bilateral Salpingo-Oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
Q26781177	Biological markers of invasive breast cancer
Q38893074	Biology and Management of Patients With Triple-Negative Breast Cancer
Q38696790	Biomarker assessment and molecular testing for prognostication in breast cancer
Q41708696	Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification.
Q26863672	Biomarker validation and testing
Q48353102	Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Q38150774	Biomarkers of drugs targeting HER-family signalling in cancer.
Q92011636	Biomarkers to diagnose metastatic breast carcinoma to the pancreas: A case report and update
Q52911366	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.
Q58608725	Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features
Q90655998	Brain metastasis-related microRNAs in patients with advanced breast cancer
Q33666339	Breast Biomarkers-Comparison on Whole Section and Tissue Microarray Section
Q35758871	Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells
Q92916959	Breast Cancer Heterogeneity in Primary and Metastatic Disease
Q97423486	Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
Q38812876	Breast Cancers Detected at Screening MR Imaging and Mammography in Patients at High Risk: Method of Detection Reflects Tumor Histopathologic Results
Q35674339	Breast Tissue Composition and Immunophenotype and Its Relationship with Mammographic Density in Women at High Risk of Breast Cancer
Q64892768	Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
Q42004516	Breast cancer and Flammer syndrome: any symptoms in common for prediction, prevention and personalised medical approach?
Q58703254	Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients
Q57112840	Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
Q41545885	Breast cancer in Angola, molecular subtypes: a first glance
Q48102254	Breast cancer stem cells are involved in Trastuzumab resistance through the HER2 modulation in 3D culture.
Q40076929	Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis
Q38386346	Breast cancer under age 40: a different approach
Q54466502	Breast cancer: updated guideline recommendations for HER2 testing.
Q42377436	Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification
Q38887777	Breast fine needle aspiration continues to be relevant in a large academic medical center: experience from Massachusetts General Hospital
Q38255904	Breast pathology second review identifies clinically significant discrepancies in over 10% of patients
Q37371183	Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections
Q33840191	Budget impact analysis of a breast rapid diagnostic unit
Q49498310	Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Q38365298	CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer
Q34590820	CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast
Q37094941	CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ.
Q64284492	CD9 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Lobular Carcinoma
Q42317491	CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers
Q39358281	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial
Q33728102	CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient
Q89172410	CXCL12 chemokine and CXCR4 receptor: association with susceptibility and prognostic markers in triple negative breast cancer
Q38974995	Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease?
Q36605624	Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary
Q35879887	Cancer biomarker discovery and validation
Q42472874	Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Q58556410	Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma
Q36544839	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
Q64899508	Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study.
Q61806002	Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer
Q34371646	Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology
Q38750783	Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients.
Q59795879	Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy
Q33688726	Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study
Q91559381	Centromere 17 copy number gain reflects chromosomal instability in breast cancer
Q47164059	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?
Q40188581	Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy.
Q90619966	Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value
Q33739585	Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer
Q48093728	Changes in c-erbB-2 Immunoexpression in Feline Endometrial Adenocarcinomas.
Q37385681	Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade
Q40832706	Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients
Q37588488	Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer
Q90567499	Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases
Q50893707	Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.
Q52595390	Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Q92551228	Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts
Q43923959	Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es salaam, Tanzania
Q47593035	Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Q64934986	Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
Q64996424	Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents.
Q33697429	Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women
Q57461650	Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study
Q55647210	Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples.
Q92579947	Chromogenic in Situ Hybridization Technique versus Immunohistochemistry in Assessment of HER2/neu Status in 448 Iraqi Patients with Invasive Breast Carcinoma
Q36193912	Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.
Q35945945	Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer
Q40847702	Circulating Tumor Cells.
Q37684125	Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer
Q34042565	Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression.
Q36237815	Claudin-Low Breast Cancer; Clinical & Pathological Characteristics
Q41443052	Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint
Q42335970	Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines
Q57517727	Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative
Q47196323	Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients
Q41662380	Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Q64940482	Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.
Q90484961	Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Q64236586	Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
Q48409259	Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients
Q26800996	Clinical implications of the intrinsic molecular subtypes of breast cancer
Q40977689	Clinical outcome of brain metastases differs significantly among breast cancer subtypes
Q90149717	Clinical outcomes of an intraoperative surgical margin assessment using the fresh frozen section method in patients with invasive breast cancer undergoing breast-conserving surgery - a single center analysis
Q64096309	Clinical potential of mass spectrometry-based proteogenomics
Q36974534	Clinical predictors of long-term survival in HER2-positive metastatic breast cancer
Q41701909	Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
Q47260496	Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years
Q40811309	Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival
Q40135743	Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Q87629019	Clinical significance of a papillary adenocarcinoma component in early gastric cancer: a single-center retrospective analysis of 628 surgically resected early gastric cancers
Q38754717	Clinical utility of gene-expression signatures in early stage breast cancer
Q64237850	Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer
Q36473017	Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer
Q41956083	Clinico-Pathologic Subtypes of Breast Cancer Primary Tumors Are Related to Prognosis after Recurrence
Q91755986	Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial
Q64272441	Clinicopathologic and molecular characteristics of 44 patients with pure secretory breast carcinoma
Q92618058	Clinicopathologic characteristics of HER2-positive pure mucinous breast carcinoma: a systematic investigation into an unusual tumor
Q92389536	Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample
Q35675665	Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center
Q41198035	Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer
Q50655660	Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.
Q36820188	Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situ
Q36914879	Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast
Q40343596	Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Q104486591	Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer
Q34483478	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients
Q42386629	Coamplification with colocalization of the human epidermal growth factor receptor 2 and centromeric-17 signals on fluorescence in situ hybridization in invasive breast carcinoma: An exceedingly rare finding
Q39036665	Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas
Q99608951	Combination of preoperative fibrinogen concentration and neutrophil-to-lymphocyte ratio for prediction of the prognosis of patients with resectable breast cancer
Q49409380	Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study
Q92237440	Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer
Q93361007	Combining fluorescence-based image segmentation and automated microfluidics for ultrafast cell-by-cell assessment of biomarkers for HER2-type breast carcinoma
Q48265826	Combining multiparametric MRI with receptor information to optimize prediction of pathologic response to neoadjuvant therapy in breast cancer: preliminary results.
Q50301520	Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer.
Q55425539	Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
Q38648453	Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer
Q89171762	Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma
Q35750049	Comparative study between quantitative digital image analysis and fluorescence in situ hybridization of breast cancer equivocal human epidermal growth factor receptors 2 score 2(+) cases
Q41997321	Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry
Q51560507	Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer: A Cohort Study Emphasizing Equivocal Cases.
Q54348234	Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
Q38681307	Comparison of HER2 testing among laboratories: Our experience with review cases retested at Moffitt Cancer Center in a two-year period
Q64914379	Comparison of Molecular Subtypes of Carcinoma of the Breast in Two Different Age Groups: A Single Institution Experience.
Q47788774	Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
Q55171730	Comparison of Pathological Prognostic Stage and Anatomic Stage Groups According to the Updated Version of the American Joint Committee on Cancer (AJCC) Breast Cancer Staging 8th Edition.
Q58767252	Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform
Q45814350	Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program.
Q33574310	Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer
Q37438701	Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
Q61817310	Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples
Q37246183	Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection
Q64254353	Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2
Q55126874	Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
Q37719989	Complex IV subunit 1 defect predicts postoperative survival in hepatocellular carcinoma
Q53293967	Complexity in regulation of microRNA machinery components in invasive breast carcinoma.
Q64081080	Complicated prognostic values of CCL28 in breast cancer by subtype
Q40064664	Comprehensive Histologic Scoring to Maximize the Predictability of Pathology-generated Equation of Breast Cancer Oncotype DX Recurrence Score
Q48105836	Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Q41571663	Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy.
Q36356185	Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility.
Q38830663	Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Q40264759	Computer Aided Semi-Automated Evaluation of HER2 Immunodetection--A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy
Q34084063	Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification
Q42282776	Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients
Q92837814	Concordance of immunohistochemistry and fluorescence in situ hybridization for assessment of HER2 status in breast cancer patients in Xinjiang autonomous region, China
Q51707520	Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease.
Q92501000	Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial
Q37582617	Conditional disease-free survival among patients with breast cancer
Q35981197	Conference report from the 2015 OECI Oncology Days, Portugal, 22-24 June-tumour heterogeneity and next generation sequencing: morphology and technology
Q26747282	Confronting the Care Delivery Challenges Arising from Precision Medicine
Q98291200	Conserving the lymphatics from the arm using fluorescence imaging in patients with breast cancer at high risk of postoperative lymphedema: a pilot study
Q36559818	Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer
Q42113818	Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes
Q47763856	Contribution of germline mutations in cancer predisposition genes to tumor etiology in young women diagnosed with invasive breast cancer
Q54940119	Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study.
Q38830273	Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma.
Q48270057	Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
Q36115834	Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods
Q48087902	Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion.
Q54337373	Correlation of HER2 gene status assessment by fluorescence in situ hybridization between histological sections and cytological specimens of breast cancer.
Q34371749	Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas
Q53825199	Correlation of Immunohistochemistry and Fluorescence in Situ Hybridization for HER-2 Assessment in Breast Cancer Patients: Single Centre Experience.
Q48175913	Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013.
Q37607412	Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients.
Q36368001	Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
Q54324778	Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.
Q36116276	Cost-utility analyses of drug therapies in breast cancer: a systematic review.
Q48155048	Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?
Q35574950	Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues
Q54311366	Cystic apocrine ductal carcinoma in situ with increased EGFR expression, trisomy 7, and associated focal invasion.
Q53423659	Cytogenetic analysis of metaplastic squamous cell carcinoma of the breast inter- and intratumoral heterogeneity.
Q55409038	Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population.
Q53277939	Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma.
Q37057171	Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer
Q55027564	Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.
Q61812190	DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway
Q48177736	DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Q41705524	Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate
Q59128695	Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes
Q91693727	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study
Q39421814	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance
Q47727855	Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer
Q35586697	Defining breast cancer intrinsic subtypes by quantitative receptor expression
Q47096644	Demographic Characteristics, Survival and Prognostic Factors of Early Breast Cancer Patients with Type 2 Diabetes Mellitus: A Hospital-Based Cohort Study
Q47846945	Detection and genomic characterization of a mammary-like adenocarcinoma.
Q90280131	Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform
Q37309906	Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
Q100503891	Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing
Q92381716	Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma
Q97905188	Developing a routine lab test for absolute quantification of HER2 in FFPE breast cancer tissues using Quantitative Dot Blot (QDB) method
Q43019940	Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.
Q38611899	Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
Q38383094	Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer
Q35752868	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Q26774670	Development of Companion Diagnostics
Q65558792	Development of Electrochemical Immunosensors towards Point-of-care Cancer Diagnostics: Clinically Relevant Studies
Q36182596	Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Q37000037	Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements
Q90664744	Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study
Q93164688	Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer
Q89514068	Development of a risk-stratification scoring system for predicting lymphovascular invasion in breast cancer
Q58554058	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer
Q35043734	Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging
Q38390425	Developments in biospecimen research
Q37266321	Diagnostic Pitfalls in Papillary Lesions of the Breast: Experience from a Single Tertiary Care Center
Q36502246	Dietary effects of mead acid on N-methyl-N-nitrosourea-induced mammary cancers in female Sprague-Dawley rats
Q35813033	Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013
Q37559408	Differences in breast carcinoma immunohistochemical subtypes between immigrant Arab and European women
Q36689113	Differentiation between genetic mutations of breast cancer by breath volatolomics.
Q36544438	Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples
Q94340372	Digital and Computational Pathology: Bring the Future into Focus
Q45943609	Digital image analysis in breast pathology-from image processing techniques to artificial intelligence.
Q40107322	Digital image analysis of HER2 immunohistochemistry in gastric- and oesophageal adenocarcinoma: a validation study on biopsies and surgical specimens
Q39967968	Digital image analysis outperforms manual biomarker assessment in breast cancer.
Q89684109	Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence
Q38168792	Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.
Q38377039	Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample
Q41281294	Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
Q55066506	Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites.
Q36610188	Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be t
Q38629753	Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China
Q33685227	Distant recurrence risk following early ipsilateral breast tumor recurrence
Q58701459	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center
Q60302395	Distinct expression and prognostic value of members of the epidermal growth factor receptor family in ovarian cancer
Q40257398	Distinct prognostic roles and heterogeneity of TTF1 copy number and TTF1 protein expression in non-small cell lung cancer.
Q93036043	Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas
Q41472829	Does the 1H-NMR plasma metabolome reflect the host-tumor interactions in human breast cancer?
Q90093747	Downregulation of N-myc and STAT Interactor Protein Predicts Aggressive Tumor Behavior and Poor Prognosis in Invasive Ductal Carcinoma
Q57039390	Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues
Q38815180	Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples
Q91741236	Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescent in situ hybridization for ascertaining Her2 status of breast cancer
Q90568473	Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients
Q99418051	Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
Q38696796	Ductal carcinoma in situ - update on risk assessment and management
Q92377712	Ductal carcinoma in situ of the breast: immune cell composition according to subtype
Q37490083	Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression
Q47107525	EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
Q90297672	ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling
Q49568845	ERBB2 mutation: A promising target in non-squamous cervical cancer.
Q53645637	Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival.
Q47161842	Eco-Friendly Formulated Zinc Oxide Nanoparticles: Induction of Cell Cycle Arrest and Apoptosis in the MCF-7 Cancer Cell Line
Q35098320	Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.
Q37597853	Effective implementation of novel MET pharmacodynamic assays in translational studies
Q38375607	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Q54216352	Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.
Q50595872	Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.
Q39683758	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
Q44834419	Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients
Q54957080	Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.
Q38624619	Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients
Q90652072	Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers
Q53059106	Endobronchial Pagetoid Spread of a Breast Carcinoma Metastatic to the Lung.
Q55113713	Ensemble outlier detection and gene selection in triple-negative breast cancer data.
Q92922203	Epidermal Growth Factor and Adenosine Triphosphate Induce Natrium Iodide Symporter Expression in Breast Cancer Cell Lines
Q28084216	Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer
Q58608173	Epigenetic profiling for the molecular classification of metastatic brain tumors
Q34011318	Epigenomic alterations in breast carcinoma from primary tumor to locoregional recurrences.
Q59339939	Epigenomic profiling of archived FFPE tissues by enhanced PAT-ChIP (EPAT-ChIP) technology
Q36145725	Epithelial-Mesenchymal Transition Phenotype Is Associated with Clinicopathological Factors That Indicate Aggressive Biological Behavior and Poor Clinical Outcomes in Invasive Breast Cancer.
Q47137308	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study
Q91633172	Establishment of Simple Nomograms for Predicting Axillary Lymph Node Involvement in Early Breast Cancer
Q64086596	Establishment of primary human breast cancer cell lines using "pulsed hypoxia" method and development of metastatic tumor model in immunodeficient mice
Q88752161	Estrogen receptor (ESR1) mutation in bone metastases from breast cancer
Q38842674	Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review
Q89886956	Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-anal
Q36595121	Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers
Q93377567	Evaluation of Estrogen and Progesterone Receptors and Her-2 Expression with Grading in the Fine-needle Aspirates of Patients with Breast Carcinoma
Q37367705	Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer
Q47377842	Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy
Q37607969	Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period
Q49594093	Evaluation of Vascular Proliferation in Molecular Subtypes of Breast Cancer
Q50016491	Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Q88680520	Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study
Q90282144	Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A
Q40180964	Evidence for the association of Epstein-Barr Virus in breast cancer in Indian patients using in-situ hybridization technique
Q93384504	Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas
Q88391705	Expanding definitions of HER2 positivity
Q37629540	Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer
Q41205623	Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis
Q90537994	Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy
Q89128693	Expression of Genes for Methylxanthine Pathway-Associated Enzymes Accompanied by Sex Steroid Receptor Status Impacts Breast Carcinoma Progression
Q92286634	Expression of Podoplanin in Mammary Cancers in Female Dogs
Q35583904	Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics
Q38423284	Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer
Q37547952	Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Q47149324	Expression of and correlation between BCL6 and ZEB family members in patients with breast cancer
Q51609262	Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma.
Q52938712	Expression of cancer-associated fibroblast-related proteins in adipose stroma of breast cancer.
Q36292201	Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions
Q58083308	Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion
Q36342637	Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma
Q36014223	Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status
Q48141048	Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome
Q37075615	Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study
Q57105820	F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men
Q51168093	FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
Q51503743	FISH in chips: turning microfluidic fluorescence in situ hybridization into a quantitative and clinically reliable molecular diagnosis tool.
Q48550447	FISH in triple-negative breast cancer: a possible strategy for the future?
Q37406841	FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics.
Q51062308	FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells.
Q55517966	FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
Q48348098	Factors predictive of occult nipple-areolar complex involvement in patients with carcinoma in situ of the breast.
Q35803396	Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer
Q37148958	Fascin-1 as a novel diagnostic marker of triple-negative breast cancer
Q90717131	Fast fluorescence in situ hybridisation for the enhanced detection of MET in non-small cell lung cancer
Q38399858	Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients.
Q92083474	Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in Colorectal Cancers
Q35743009	Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer
Q50955504	Fibrotic focus: An important parameter for accurate prediction of a high level of tumor-associated macrophage infiltration in invasive ductal carcinoma of the breast.
Q36546414	First description of a sporadic breast cancer in a woman with BRCA1 germline mutation
Q34104204	First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer
Q47965803	First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer
Q100758028	Fluorescence in situ hybridisation analysis of human epidermal growth factor receptor 2 status for breast cancer cases in Brunei Darussalam
Q53364971	Fluorescence in situ hybridization (FISH) results in HER2 score 1+ and 2+ breast cancers.
Q89668743	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients
Q35083252	For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
Q55155438	Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Q40324533	Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry
Q87232807	Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort
Q42491917	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
Q57793316	Frequent ESR1 and CDK Pathway Copy Number Alterations in Metastatic Breast Cancer
Q54284515	Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
Q28084982	From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
Q35284728	Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study
Q53362356	Fut3 role in breast invasive ductal carcinoma: Investigating its gene promoter and protein expression.
Q50013621	GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer
Q51502502	GATA3 expression in primary vulvar Paget disease: a potential pitfall leading to misdiagnosis of pagetoid urothelial intraepithelial neoplasia.
Q33761830	GD2 expression in breast cancer.
Q41714879	Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method
Q34458036	Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method
Q37447938	Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines
Q40269605	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Q37377544	Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma
Q36844915	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology
Q47882632	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma
Q40505249	Genetic code expansion for multiprotein complex engineering.
Q37372455	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer
Q55394663	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
Q37706844	Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray
Q38407595	Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup
Q51521953	Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers.
Q42495798	Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures
Q60908056	Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
Q90393213	Genomic alterations associated with HER2+ breast cancer risk and clinical outcome in response to trastuzumab
Q58801101	Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications
Q46225087	Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors.
Q36366309	Genomic landscape of adenoid cystic carcinoma of the breast
Q42498238	Genomic profiling of breast cancer in African-American women using MammaPrint.
Q42510239	Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.
Q92589578	Genomic profiling of multiple breast cancer reveals inter-lesional heterogeneity
Q92610423	Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERRB3 alterations
Q92627804	Genomics applied to the treatment of breast cancer
Q92830555	Genomics-Enabled Precision Medicine for Cancer
Q36847816	Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories
Q54579368	Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer.
Q34202981	GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
Q37687943	Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry
Q36695807	Guidelines for cytogenetic investigations in tumours
Q36762236	HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens
Q50115014	HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Q36094918	HER-2 and EGFR mRNA Expression and Its Relationship with Versican in Malignant Matrix-Producing Tumors of the Canine Mammary Gland.
Q37708897	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
Q92839110	HER-2 status and its clinicopathologic significance in breast cancer in patients from southwest China: re-evaluation of correlation between results from FISH and IHC
Q91997875	HER-2/Neu and Hormone Receptor Analysis in Breast Carcinomas and Their Association with Clinicopathologic Parameters
Q34506951	HER-3 targeting alters the dimerization pattern of ErbB protein family members in breast carcinomas
Q64063349	HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Q39983856	HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
Q48147789	HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category
Q39442160	HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials
Q51175484	HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer.
Q50125137	HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility.
Q33686182	HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancer
Q36724623	HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder
Q33925610	HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patients
Q28078111	HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists
Q46188099	HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics
Q38914809	HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations.
Q27026178	HER2 as a therapeutic target in head and neck squamous cell carcinoma
Q90208904	HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma
Q92465974	HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
Q47097049	HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2-negative patients.
Q90626593	HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population
Q47370686	HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
Q38364900	HER2 expression status in diverse cancers: review of results from 37,992 patients
Q35929360	HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide
Q40714642	HER2 gene copy number and breast cancer-specific survival
Q26741253	HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice
Q92685589	HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
Q48330458	HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features
Q35211263	HER2 in solid tumors: more than 10 years under the microscope; where are we now?
Q37075632	HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
Q47965547	HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
Q51541370	HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
Q40419939	HER2 mRNA transcript quantitation in breast cancer
Q61446731	HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women
Q36151207	HER2 status determination: analyzing the problems to find the solutions
Q36014239	HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features.
Q90593024	HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features
Q38326102	HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
Q39174711	HER2 testing in gastric cancer: results of a German expert meeting
Q92577910	HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study
Q37588232	HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
Q92004464	HER2-Positive Conversion in a Metastatic Liver Focus in Late Recurrent Breast Cancer
Q35551522	HER2-directed therapy: current treatment options for HER2-positive breast cancer
Q34499609	HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
Q39034850	HER2-positive breast cancer
Q38648765	HER2-positive breast cancer is lost in translation: time for patient-centered research
Q40391145	HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable
Q39040859	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Q33741544	HER2/neu Testing In 432 Consecutive Breast Cancer Cases using FISH and IHC - A Comparative Study
Q34499615	HER2/neu testing in primary colorectal carcinoma
Q35748129	HER2/neu-directed therapy for biliary tract cancer
Q36040463	HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
Q40649343	HMGA1 overexpression is associated with a particular subset of human breast carcinomas
Q33823200	HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells
Q37644205	Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy
Q33623561	Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.
Q44347751	Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization
Q54356587	Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
Q33767081	Heterogeneity of Diffusion-Weighted Imaging in Tumours and the Surrounding Stroma for Prediction of Ki-67 Proliferation Status in Breast Cancer
Q57058202	High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients
Q55345031	High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.
Q37142882	High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.
Q57124774	High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer
Q41297799	High excision repair cross-complementation group 1 expression is associated with favorable prognostic factors in breast cancer
Q47561567	High expression of PU.1 is associated with Her-2 and shorter survival in patients with breast cancer
Q53192082	High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers.
Q37074050	High prevalence of luminal B breast cancer intrinsic subtype in Colombian women
Q35203546	High tumor budding stratifies breast cancer with metastatic properties
Q37682595	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Q91117914	High-content, cell-by-cell assessment of HER2 overexpression and amplification: a tool for intratumoral heterogeneity detection in breast cancer
Q64264397	Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era
Q38944865	Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer.
Q53130487	Higher expression of EpCAM is associated with poor clinical and pathological responses in breast cancer patients undergoing neoadjuvant chemotherapy.
Q64113608	Highly Multiplexed Fluorescence in Situ Hybridization for in Situ Genomics
Q53512628	Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.
Q49061414	Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.
Q92716347	Homologous recombination DNA repair defects in PALB2-associated breast cancers
Q64094297	Hormone Receptors and Human Epidermal Growth Factor (HER2) Expression in Fine-Needle Aspirates from Metastatic Breast Carcinoma - Role in Patient Management
Q92293794	Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies
Q92064459	Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands
Q99237864	Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors
Q90781848	Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel
Q34223494	Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications
Q48219599	Human Metaplastic Breast Carcinoma and Decorin
Q64039988	Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's disease
Q35038694	Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features
Q39661792	Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: Results from a large, multicountry study
Q38626665	Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
Q36450387	Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting.
Q37200784	Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology
Q36392789	Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy?
Q37013995	Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma
Q49412994	Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms
Q48336597	Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
Q55381932	Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Q42003695	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
Q61447409	Image Analysis of HER2 Immunohistochemical Staining of Surgical Breast Cancer Specimens
Q40217601	Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma
Q38401251	Imaging Surveillance for Survivors of Breast Cancer: Correlation between Cancer Characteristics and Method of Detection
Q35870134	Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery
Q91776798	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients
Q52956295	Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable.
Q64999098	Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray.
Q64235723	Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast Carcinomas
Q41809618	Immunohistochemical Investigation of HER/AKT/mTOR Pathway and Cellular Adhesion Molecules in Urothelial Carcinomas
Q33741582	Immunohistochemical Study of MUC1, MUC2 and MUC5AC Expression in Primary Breast Carcinoma
Q35159751	Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy.
Q51777015	Immunohistochemical analysis of T-type calcium channels in acquired melanocytic naevi and melanoma.
Q57107439	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing
Q48070124	Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test
Q92281250	Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma
Q35759456	Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests.
Q51728141	Immunohistochemical expression profiles of solute carrier transporters in alpha-fetoprotein-producing gastric cancer.
Q34029360	Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas
Q40987749	Immunohistochemistry Heterogeneity in Reported Breast Cancer Demographics From India: Triple-Negative Breast Cancer Rates Could Be Lower Than Suggested in Pooled Meta-Analysis
Q55364226	Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.
Q92830547	Immunohistochemistry-Enabled Precision Medicine
Q49646394	Immunophenotypic profile of tumor buds in breast cancer.
Q47716532	Impact of 2013 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2 Fluorescent In Situ Hybridization Testing in Breast Cancers : Experience From a National Reference Laboratory
Q92451331	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study
Q57470007	Impact of Deep Learning Assistance on the Histopathologic Review of Lymph Nodes for Metastatic Breast Cancer
Q89357387	Impact of Micrometastatic Axillary Nodes on Survival of Breast Cancer Patients with Tumors ≤2 cm
Q35810073	Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience
Q40979375	Impact of RASSF1A gene methylation on the metastatic axillary nodal status in breast cancer patients
Q40338226	Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer
Q92354821	Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
Q44541840	Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research
Q50075112	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Q64998946	Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Q99630222	Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database
Q30369607	Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
Q48142637	Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines
Q53095268	Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study.
Q91272391	Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
Q30996906	Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data
Q64961265	Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study.
Q92691435	Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort
Q45851017	Implementing personalized cancer care
Q50056206	Improving accuracy of breast cancer biomarker testing in India.
Q53118370	In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases.
Q40919195	In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading
Q33812042	In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients
Q36109108	In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
Q86842053	In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival
Q51367692	Inconsistent Results With Different Secondary Reflex Assays for Resolving HER2 Status.
Q45134639	Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System
Q90700166	Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice
Q49466873	Increased expression of mitochondrial transcription factor A and nuclear respiratory factor-1 predicts a poor clinical outcome of breast cancer
Q40770256	Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
Q92990334	Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging
Q88205410	Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer
Q38777813	Influence of vitamin D signaling on hormone receptor status and HER2 expression in breast cancer
Q41012013	Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).
Q47291975	Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer
Q91526464	Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling
Q64957213	Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer.
Q92890756	Intense basolateral membrane staining indicates HER2 positivity in invasive micropapillary breast carcinoma
Q91796421	Interleukin-17 and matrix metalloprotease-9 expression in the mycetoma granuloma
Q45162655	Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer.
Q52974218	Internal mammary node adenopathy on breast MRI and PET/CT for initial staging in patients with operable breast cancer: prevalence and associated factors.
Q54962807	Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates.
Q92920230	Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients
Q33841547	Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
Q35633666	Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
Q59132342	Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
Q52618828	Intratumoral Heterogeneity of ERBB2 Amplification and HER2 Expression in Micropapillary Urothelial Carcinoma.
Q47176267	Intrinsic Subtypes of Breast Cancers Initially Assessed as Probably Benign or of Low Suspicion on Ultrasonography Differ According to Tumor Size
Q89572743	Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay
Q64115873	Introduction to Digital Image Analysis in Whole-slide Imaging: A White Paper from the Digital Pathology Association
Q96171987	Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas
Q30416537	Invasive cribriform carcinoma of the breast: A report of nine cases and a review of the literature
Q35905268	Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
Q53462538	Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?
Q38221886	Investigational therapies targeting the ErbB family in oesophagogastric cancer
Q31048851	Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment
Q58605259	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)
Q36973465	KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors
Q50045477	Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients.
Q51015726	Ki-67 as a Prognostic Factor in Feline Mammary Carcinoma: What Is the Optimal Cutoff Value?
Q37658237	Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
Q37596690	Ki-67 as a prognostic marker according to breast cancer molecular subtype
Q91939079	Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study
Q52680900	Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.
Q37578368	LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
Q47403498	LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness
Q47138636	Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers.
Q48249374	Lacrimal gland ductal carcinomas: Clinical, Morphological and Genetic characterization and implications for targeted treatment.
Q100961545	Landscape of clinically actionable mutations in breast cancer 'A cohort study'
Q38992588	Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer
Q48012424	Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma
Q33802722	Lectin histochemistry reveals SNA as a prognostic carbohydrate-dependent probe for invasive ductal carcinoma of the breast: a clinicopathological and immunohistochemical auxiliary tool
Q38213543	Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy
Q92433344	Life-threatening metastasis was suppressed by trastuzumab containing regimen in a patient with Her2-negative breast cancer
Q60539186	Lifetime-engineered NIR-II nanoparticles unlock multiplexed in vivo imaging
Q55070669	Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer.
Q37367411	Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment
Q28083233	Long term side effects of adjuvant chemotherapy in patients with early breast cancer
Q90418604	Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement
Q41142443	Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report
Q38413284	Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer
Q41547969	Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.
Q58550839	Low PR in ER(+)/HER2(-) breast cancer: high rates of TP53 mutation and high SUV
Q64101361	Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology
Q35611160	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.
Q92876894	Luminal B is the Most Common Intrinsic Molecular Subtypes of Invasive Ductal Breast Carcinoma Patients in East Kalimantan, Indonesia
Q64905115	Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy.
Q39286355	MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas
Q34116451	MMP-9 expression varies according to molecular subtypes of breast cancer
Q89948271	MRI Radiomic Features: Association with Disease-Free Survival in Patients with Triple-Negative Breast Cancer
Q47389056	MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
Q47391427	MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene
Q42363795	MYC Immunohistochemistry Predicts MYC Rearrangements by FISH.
Q36907273	MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
Q92509640	Machine learning-based prediction of breast cancer growth rate in vivo
Q64923060	Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.
Q38317182	Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches.
Q35920570	Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer
Q51148400	Male Breast Cancer.
Q39022639	Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Q64067550	Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort
Q42516409	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes
Q41545259	MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.
Q51252463	Margins: a status report from the Annual Meeting of the American Society of Breast Surgeons.
Q36009610	Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer
Q36510875	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
Q26752780	Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It
Q51107564	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.
Q54350939	Metabolic differences in estrogen receptor-negative breast cancer based on androgen receptor status.
Q64232817	Metachronous bilateral triple-negative breast cancer associated with neurofibromatosis type 1: A case report
Q91361607	Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy
Q35911470	Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. .
Q91766790	Metastatic Breast Cancer in Kenya: Presentation, Pathologic Characteristics, and Patterns-Findings From a Tertiary Cancer Center
Q37743489	MiRNA-27a promotes the proliferation and invasion of human gastric cancer MGC803 cells by targeting SFRP1 via Wnt/β-catenin signaling pathway
Q57106460	MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers
Q64089665	Microcalcification and BMP-2 in breast cancer: correlation with clinicopathological features and outcomes
Q27316870	Microfluidic platform combining droplets and magnetic tweezers: application to HER2 expression in cancer diagnosis
Q48194558	Microfluidics-assisted fluorescence in situ hybridization for advantageous human epidermal growth factor receptor 2 assessment in breast cancer
Q37130372	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations
Q55177941	Micromolecular methods for diagnosis and therapeutic strategy: a case study.
Q53070572	Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.
Q64109020	Minimal prognostic significance of sentinel lymph node metastasis in patients with cT1-2 and cN0 breast cancer
Q92281997	Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability
Q53523972	Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.
Q26772870	Molecular Imaging of Biomarkers in Breast Cancer
Q28072513	Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
Q64106622	Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells
Q50045468	Molecular Subtypes and Local-Regional Control of Breast Cancer.
Q42511857	Molecular Subtypes of Breast Cancers from Myanmar Women: A Study of 91 Cases at Two Pathology Centers
Q49648562	Molecular Subtypes of Indonesian Breast Carcinomas - Lack of Association with Patient Age and Tumor Size
Q26751172	Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer
Q37710556	Molecular Testing for Gastrointestinal Cancer.
Q33729715	Molecular Testing of Lung Cancers
Q42687892	Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population
Q26800626	Molecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case Presentation
Q92538958	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes
Q91904654	Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing
Q64921722	Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target.
Q51711213	Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Q35965925	Molecular heterogeneity in adjacent cells in triple-negative breast cancer
Q38236904	Molecular markers for breast cancer diagnosis, prognosis and targeted therapy
Q93000430	Molecular markers in uterine serous cancer: Correlation between endometrial biopsy and hysterectomy specimens
Q33731350	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
Q34723641	Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.
Q42508624	Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas.
Q38184381	Molecular tests as prognostic factors in breast cancer
Q49545664	Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact
Q41821797	Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification
Q39014708	Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets
Q48104335	Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
Q100525979	Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma
Q39467942	Multiplex Ligation-dependent Probe Amplification Can Clarify HER2 Status in Gastric Cancers with "Polysomy 17".
Q33688612	Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study
Q38758647	Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections
Q88258261	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases
Q34764681	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications
Q34654793	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
Q46107985	Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.
Q33450398	NDER: A novel web application using annotated whole slide images for rapid improvements in human pattern recognition
Q92617209	NDRG3 protein expression is associated with aggressive biologic phenotype and unfavorable outcome in patients with invasive breast cancer
Q42366735	NanoString nCounter® Approach in Breast Cancer: A Comparative Analysis with Quantitative Real-Time Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry.
Q26782856	NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer
Q64238212	Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments
Q53084708	Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer.
Q42669105	Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
Q57108415	Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
Q39375196	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Q38658509	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Q99614331	Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase
Q48247756	Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
Q92552262	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri
Q64981225	Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial.
Q38692311	Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.
Q92953592	Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Q48111187	New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Q47105039	New Agents for the Management of Advanced HER2-Positive Breast Cancer
Q89612527	New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Q38782016	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer
Q51232753	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
Q64080457	Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management
Q51195482	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Q26801745	Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection
Q27324543	Novel method for rapid in-situ hybridization of HER2 using non-contact alternating-current electric-field mixing
Q98467126	Novel targeted therapies for metastatic breast cancer
Q33887682	Novel therapeutic strategies in the treatment of triple-negative breast cancer
Q59135024	OCT4, SOX2, and NAN OG positive expression correlates with poor differentiation, advanced disease stages, and worse overall survival in HER2 + breast cancer patients
Q38436984	Obesity and breast cancer: not only a risk factor of the disease
Q55285404	Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study.
Q36280470	Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
Q101564262	Omitting radiotherapy is safe in breast cancer patients ≥ 70 years old after breast-conserving surgery without axillary lymph node operation
Q38420347	Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer
Q92716047	Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Q39450470	Operation with less adjuvant therapy for elderly breast cancer.
Q54197932	Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?
Q35239634	Optimal systemic therapy for early breast cancer in women: a clinical practice guideline
Q35673706	Optimizing HER2 assessment in breast cancer: application of automated image analysis
Q33756398	Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer
Q35896153	Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute
Q38811462	Organochlorine pesticides accumulation and breast cancer: A hospital-based case-control study
Q37103673	Outcome Disparities in African American Compared with European American Women with ER+HER2- Tumors Treated within an Equal-Access Health Care System
Q64952029	Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
Q40719325	Outcome of pN0 Triple-Negative Breast Cancer with or without Lymph Node Irradiation: A Single Institution Experience.
Q51136930	Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Q35687851	Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.
Q38378337	Ovarian carcinoma diagnosis: the clinical impact of 15 years of change
Q34478105	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis
Q37714123	Overexpression of TMPRSS4 promotes tumor proliferation and aggressiveness in breast cancer
Q55176796	Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer.
Q34675545	P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer
Q46990125	PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations
Q37704352	PD-L1 Expression in Lung Cancer
Q50035044	PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Q64955321	PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis.
Q50068205	PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Q35552005	PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
Q47095045	PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.
Q90645887	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Q38252702	Pathological examination of breast cancer biomarkers: current status in Japan
Q33873330	Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
Q48148198	Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.
Q92433445	Pathological response of salivary duct carcinoma to trastuzumab and docetaxel therapy
Q37316607	Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis
Q35663687	Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
Q26795376	Personalized Medicine: Genomics Trials in Oncology
Q47199187	Personalized cancer therapy: leveraging a knowledge base for clinical decision-making
Q38848389	Perspectives of HER2-targeting in gastric and esophageal cancer
Q33364587	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle
Q49668714	Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety stu
Q98906952	Pervasive chromosomal instability and karyotype order in tumour evolution
Q38573858	Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy
Q48212691	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Q93039201	Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 1 (PREX1) is a Novel Predictor of Prognosis for Breast Cancer Patients: A Retrospective Case Series
Q57469231	Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab
Q33810500	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations
Q55265106	Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
Q47209176	Physician interpretation of genomic test results and treatment selection.
Q36432099	Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
Q34134105	Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas
Q38726641	Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review
Q35647723	Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases
Q47161220	Pleomorphic lobular carcinoma: is it more similar to a classic lobular cancer or to a high-grade ductal cancer?
Q94474399	Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy
Q57071024	Polymorphisms in and are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
Q64095962	Polymorphisms in are associated with age and differentiation of triple-negative breast cancer patients
Q36640368	Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility.
Q57025247	Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype
Q38833288	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression
Q90315028	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022
Q88598954	Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial
Q42316809	Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis
Q50197859	Precise pathologic diagnosis and individualized treatment improve the outcomes of invasive micropapillary carcinoma of the breast: a 12-year prospective clinical study.
Q38551394	Precision medicine for metastatic breast cancer--limitations and solutions.
Q36963554	Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
Q90677931	Predicting the presence of breast cancer using circulating small RNAs, including those in the extracellular vesicles
Q49912739	Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients
Q94526113	Prediction of Pathologic Complete Response by Ultrasonography and Magnetic Resonance Imaging After Neoadjuvant Chemotherapy in Patients with Breast Cancer
Q61802758	Prediction of high nodal burden with ultrasound and magnetic resonance imaging in clinically node-negative breast cancer patients
Q58101133	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
Q55362114	Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression.
Q98386288	Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
Q40852747	Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer
Q39170872	Predictive biomarkers along gastric cancer pathogenetic pathways
Q38687963	Predictive factors on outcomes in metaplastic breast cancer.
Q38257364	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues
Q55066764	Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Q64998084	Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy.
Q59330044	Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer
Q37056933	Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving Surgery
Q37492154	Predictors of Surgical Margin Following Breast-Conserving Surgery: A Large Population-Based Cohort Study
Q37130345	Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43
Q38859150	Preoperative MRI features associated with lymphovascular invasion in node-negative invasive breast cancer: A propensity-matched analysis.
Q90610229	Preoperative axillary nodal staging with ultrasound and magnetic resonance imaging: predictive values of quantitative and semantic features
Q34967515	Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
Q57300518	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib
Q33651817	Presence of human papillomavirus DNA in breast cancer: a Spanish case-control study
Q89537639	Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer
Q43526241	Prevalence of women with early-stage breast cancer receiving active management using electronic health records from oncology clinics in the United States
Q30316383	Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).
Q55279483	Primary ductal adenocarcinoma of lacrimal gland: Two case reports and review of the literature.
Q34121611	Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype.
Q27012540	Profile of neratinib and its potential in the treatment of breast cancer
Q39166261	Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer - a Single Centre Study. (PPLB - 01).
Q33646271	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers
Q38687389	Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients
Q37735963	Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer
Q37176151	Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer
Q53702177	Prognostic Significance of Serum Vitamin D Levels in Egyptian Females with Breast Cancer
Q36299320	Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
Q94593638	Prognostic Significance of the Tumor-Stromal Ratio in Invasive Breast Cancer and a Proposal of a New Ts-TNM Staging System
Q64917707	Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer
Q89465480	Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab
Q35593081	Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly
Q89644502	Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis
Q47734351	Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
Q38778532	Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer
Q50457473	Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
Q101403266	Prognostic and predictive parameters in breast pathology: a pathologist's primer
Q37327661	Prognostic and predictive value of Ki-67 in triple-negative breast cancer
Q92819254	Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response
Q36180689	Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer
Q34582515	Prognostic factors of second primary contralateral breast cancer in early-stage breast cancer.
Q38749528	Prognostic impact of HER-2 Subclonal Amplification in breast cancer
Q35148813	Prognostic impact of HOTAIR expression is restricted to ER-negative breast cancers.
Q52880311	Prognostic implications of securin expression and sub-cellular localization in human breast cancer.
Q34996098	Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients
Q93072009	Prognostic markers in salivary gland cancer and their impact on survival
Q37175089	Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
Q36600002	Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis
Q42464923	Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.
Q48261136	Prognostic significance of CD9 expression differs between tumour cells and stromal immune cells, and depends on the molecular subtype of the invasive breast carcinoma.
Q57298068	Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer
Q44217841	Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers
Q37671450	Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients
Q61798870	Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
Q36107543	Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques
Q89677965	Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer
Q26798078	Progress in adjuvant chemotherapy for breast cancer: an overview
Q52589023	Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.
Q51017227	Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
Q88468281	Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas
Q93270250	Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients
Q29011698	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Q38748131	Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications.
Q35816286	Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
Q58416668	Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work
Q38596988	Quality assurance in clinical trials--the role of pathology
Q36134039	Quantification of HER2 by Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded (FFPE) Breast Cancer Tissues.
Q64112956	Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes
Q53581875	Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.
Q93089134	Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
Q41601026	Quantitative diagnosis of HER2 protein expressing breast cancer by single-particle quantum dot imaging
Q38633233	Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness.
Q35343184	Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival
Q35251561	Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic
Q36261449	Quantitative real-time polymerase chain reaction is an alternative method for the detection of HER-2 amplification in formalin-fixed paraffin-embedded breast cancer samples
Q35347732	Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer
Q48142619	Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
Q38370716	Radiation therapy in the locoregional treatment of triple-negative breast cancer
Q54116157	Radioiodinated Small Molecule Tyrosine Kinase Inhibitor for HER2 Selective SPECT Imaging.
Q36271681	Radiomic analysis reveals DCE-MRI features for prediction of molecular subtypes of breast cancer
Q48018514	Raman-Encoded Molecular Imaging with Topically Applied SERS Nanoparticles for Intraoperative Guidance of Lumpectomy
Q91130415	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
Q88385844	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results
Q55068762	Rapid fluorescence in situ hybridisation (FISH) for HER2 (ERBB2) assessment in breast and gastro-oesophageal cancer.
Q55302749	Rapid micro fluorescence in situ hybridization in tissue sections.
Q55346946	Rapid progression of a granulocyte colony-stimulating factor-producing liver tumor metastasized from esophagogastric junction cancer: A case report and literature review.
Q64284818	Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant
Q36085254	Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
Q31023009	Real-world data in the molecular era-finding the reality in the real world
Q93106855	Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients
Q54269156	Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.
Q55353691	Recent Advances in the Treatment of Breast Cancer.
Q92713306	Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer
Q28083123	Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates
Q64078518	Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer
Q97070217	Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution
Q30814798	Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.
Q55003632	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.
Q35710389	Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer
Q53227861	Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
Q38618238	Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks
Q54198492	Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Q92836078	Relationship Study of The Verified H uman Epidermal Growth Factor Receptor 2 Amplification with Other Tumor Markers and Clinicohistopathological Characteristics in Patients with Invasive Breast Cancer, Using Chromogenic In Situ Hybridization
Q58801931	Relationship between gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
Q92413714	Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Q92270942	Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas
Q51396553	Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
Q54207067	Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study.
Q48719284	Reliability of the Ki67-Labelling Index in Core Needle Biopsies of Luminal Breast Cancers is Unaffected by Biopsy Volume
Q88391702	Reply to Commentary on 'HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features'
Q36168078	Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer
Q35525379	Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule
Q33632008	Reproductive risk factors and breast cancer subtypes: a review of the literature
Q38420000	Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size
Q36260485	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing.
Q35539538	Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study
Q42360663	Response: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab 2014;29:536-44, Min Jung Jung et al.).
Q40614123	Resting heart rate as a prognostic factor for mortality in patients with breast cancer
Q91760466	Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
Q47410999	Retrospective analysis of the association between human epidermal growth factor receptor 2 amplification and chromosome enumeration probe 17 status in patients with breast cancer
Q33433275	Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
Q38662712	Review: circulating tumor cells in the practice of breast cancer oncology.
Q50271137	Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.
Q39150776	Rifaximin for Pertuzumab-Related GI Toxicities
Q35949292	Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers
Q58694213	Risk factors for the development of brain metastases in patients with HER2-positive breast cancer
Q93271903	Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis
Q40490703	Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
Q61623284	Robust identification of target genes and outliers in triple-negative breast cancer data
Q33858981	Role of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China.
Q63247308	Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer
Q34004215	Role of the neural niche in brain metastatic cancer
Q59804254	RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples
Q38882282	S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Q38420953	SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Q33643210	SUSD2 promotes tumor-associated macrophage recruitment by increasing levels of MCP-1 in breast cancer
Q92814902	Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
Q37498654	Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
Q60913102	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
Q47644645	Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Q53121949	Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.
Q88766337	Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute
Q38199005	Sarcoidosis vs. Sarcoid-like reactions: The Two Sides of the same Coin?
Q90094958	Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
Q91629028	Sentinel Lymph Node Biopsy Pathology and 2-Year Postsurgical Recurrence of Breast Cancer in Kenyan Women
Q91709234	Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget's disease
Q41698982	Serum 25-hydroxyvitamin D deficiency and increased risk of breast cancer among Korean women: a case-control study.
Q37109466	Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status
Q38914932	Short formalin fixation and rapid microwave processing do not affect HER2 testing
Q92812431	Should Genetic Testing for Cancer Predisposition Be Standard-of-Care for Women with Invasive Breast Cancer? The Murtha Cancer Center Experience
Q36847236	Significance of Matrix Metalloproteinase 9 Expression as Supporting Marker to Cytokeratin 19 mRNA in Sentinel Lymph Nodes in Breast Cancer Patients
Q40214905	Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy
Q61796812	Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine
Q58567273	Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy
Q35174533	Significance of rat mammary tumors for human risk assessment
Q57477210	Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2
Q47392563	Single-cell heterogeneity in ductal carcinoma in situ of breast.
Q91176710	Single-cell protein profiling in microchambers with barcoded beads
Q47561778	Solid papillary carcinoma of the breast with an associated Cytokeratin 7- negative Paget's disease of the nipple. Report of a first case.
Q55280468	Somatic mutations in early onset luminal breast cancer.
Q33914716	Somatic mutations in leukocytes infiltrating primary breast cancers
Q47133482	Somatic mutations in salivary duct carcinoma and potential therapeutic targets.
Q48088751	Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
Q38747685	Sonographic Phenotypes of Molecular Subtypes of Invasive Ductal Cancer in Automated 3-D Breast Ultrasound
Q34283751	Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study
Q50941816	Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Q40409180	St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study.
Q49494949	Standardization and optimization of fluorescence in situ hybridization (FISH) for HER-2 assessment in breast cancer: A single center experience
Q41469992	Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients
Q37721631	Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients
Q36640187	Stromal expression of matrix metalloproteinase 2 in cancer-associated fibroblasts is strongly related to human epidermal growth factor receptor 2 status in invasive breast carcinoma
Q90711534	Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
Q38268585	Subtyping of breast cancer using reverse phase protein arrays
Q35826503	Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
Q58567692	Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status
Q37359309	Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience
Q36863215	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer
Q38209628	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline
Q38209464	Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.
Q39685521	T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab
Q91872237	T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer
Q92298870	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Q40810058	TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Q36376097	TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays
Q41660785	TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling
Q37697225	TTK is a favorable prognostic biomarker for triple-negative breast cancer survival
Q37694797	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study
Q39147161	Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer
Q39238692	Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance
Q90862850	Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Q26768119	Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives
Q99408604	Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
Q55071512	Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance.
Q34309927	Targeting MET Amplification as a New Oncogenic Driver.
Q38741697	Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
Q54962247	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.
Q35687706	The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas
Q89428605	The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment
Q36087106	The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis
Q26738677	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics
Q55026325	The FlexISH assay brings flexibility to cytogenetic HER2 testing.
Q41739963	The Genomic Landscape of Male Breast Cancers
Q64882616	The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.
Q58601441	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
Q34654520	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.
Q38700451	The Importance of Epitope Density in Selecting a Sensitive Positive IHC Control
Q40777892	The Japanese Breast Cancer Society clinical practice guidelines for pathological diagnosis of breast cancer, 2015 edition
Q52733226	The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Q48065393	The National Biomarker Development Alliance accelerating the translation of biomarkers to the clinic
Q99591067	The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
Q36653693	The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Q35874075	The Values of Combined and Sub-Stratified Imaging Scores with Ultrasonography and Mammography in Breast Cancer Subtypes
Q47372771	The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes
Q38802932	The assessment of HER2 status in breast cancer: the past, the present, and the future
Q85798864	The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer
Q37697200	The associations between mast cell infiltration, clinical features and molecular types of invasive breast cancer
Q41616706	The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers
Q52647074	The breast graded prognostic assessment is associated with the survival outcomes in breast cancer patients receiving whole brain re-irradiation.
Q91834210	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution
Q47372732	The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016.
Q33739274	The clinical significance of accompanying NME on preoperative MR imaging in breast cancer patients
Q89902062	The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma
Q37716582	The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer
Q90259059	The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status
Q38827388	The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients
Q92714905	The discordance pattern of molecular sub-types between primary and metastatic sites in Chinese breast cancer patients
Q36139739	The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study
Q53842791	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer.
Q55058089	The effect of adjuvant chemotherapy in male breast cancer: 134 cases from a retrospective study.
Q92604752	The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer
Q38192017	The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy
Q49978231	The expression of VE-cadherin in breast cancer cells modulates cell dynamics as a function of tumor differentiation and promotes tumor-endothelial cell interactions
Q26775232	The fate of chemoresistance in triple negative breast cancer (TNBC)
Q36266449	The frequency and clinical impact of HER2 alterations in lung adenocarcinoma
Q49270812	The genetic landscape of breast carcinomas with neuroendocrine differentiation
Q100752677	The genomic landscape of metastatic histologic special types of invasive breast cancer
Q33692695	The human epidermal growth factor receptor 2 screening tests for breast cancer suggested by the new updated recommendation of the american society of clinical oncology/college of american pathologists will involve a rise of the in-situ [...]
Q94521566	The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization
Q41382068	The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients.
Q38591049	The importance of surgical margins in breast cancer
Q37425427	The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case
Q36681892	The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index
Q64065309	The landscape of d16HER2 splice variant expression across HER2-positive cancers
Q92785578	The past, present, and future of HER2 (ERBB2) in cancer: Approaches to molecular testing and an evolving role in targeted therapy
Q86628860	The pre-analytical phase in surgical pathology
Q92643282	The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
Q37376414	The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy
Q46842412	The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
Q52627272	The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
Q33607142	The relationship between breast cancer molecular subtypes and mast cell populations in tumor microenvironment.
Q36110190	The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.
Q37232177	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study
Q42380390	The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform
Q48301715	The role of skin ulceration in breast carcinoma staging and outcome.
Q90484944	The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype
Q38175061	The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice
Q55033826	The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Q34268618	Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer
Q47638243	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.
Q37628969	Therapeutic implication of HER2 in advanced biliary tract cancer
Q61814603	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Q89791409	Three-dimensional radiomics of triple-negative breast cancer: Prediction of systemic recurrence
Q90317011	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer
Q55424081	Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases.
Q91974174	Towards personalized treatment for early stage HER2-positive breast cancer
Q37350784	Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Q27853001	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Q92886181	Trastuzumab in the Treatment of Pregnant Breast Cancer Patients - an Overview of the Literature
Q28077666	Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
Q34538368	Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study
Q35740877	Treatment of HER2-positive breast cancer.
Q91045690	Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016)
Q90476366	Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies
Q91989188	Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease
Q55397856	Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy.
Q90394997	Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile
Q36640582	Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα.
Q33769821	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Q33915057	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
Q36000688	Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens.
Q47146956	Tumor Heterogeneity in Breast Cancer
Q28554412	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes
Q49987138	Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy
Q47573583	Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.
Q37564576	Tumor suppressor berberine binds VASP to inhibit cell migration in basal-like breast cancer
Q64284503	Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer
Q48219547	Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.
Q49494144	Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer
Q42315538	TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy
Q47863345	Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
Q36658298	Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity
Q92726377	Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
Q91152086	Two types of primary mucinous ovarian tumors can be distinguished based on their origin
Q54293691	Two-temperature formalin fixation preserves activation states efficiently.
Q50038885	Ultrasound-Guided Restaging and Localization of Axillary Lymph Nodes After Neoadjuvant Chemotherapy for Guidance of Axillary Surgery in Breast Cancer Patients: Experience with Activated Charcoal.
Q93018293	Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study
Q36319218	Unexpected Symptomatic Pneumonitis Following Breast Tangent Radiation: A Case Report
Q35496577	Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells.
Q58803565	Unraveling the clinicopathological features driving the emergence of mutations in metastatic breast cancer
Q38932758	Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer
Q52587869	Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Q35048548	Updated UK Recommendations for HER2 assessment in breast cancer
Q28079118	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Q33817285	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Q38526035	Use of Immunohistochemical Stains in Epithelial Lesions of the Breast
Q38723467	Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients.
Q36743446	Using Copy Number Alterations to Identify New Therapeutic Targets for Bladder Carcinoma.
Q45057063	Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial
Q89986543	Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging for Prediction of Metastasis to Sentinel and Nonsentinel Nodes in Patients with Clinically Node-Negative Breast Cancer
Q87494494	Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens
Q60921036	Utility of Human Epidermal Growth Factor Receptor 2 (HER2) Retesting of Histologic Grade 3 Invasive Breast Carcinomas
Q46082799	Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer
Q57192072	Validation of CPS+EG, Neo-Bioscore, and modified Neo-Bioscore staging systems after preoperative systemic therapy of breast cancer: Protocol of a retrospective multicenter cohort study in China
Q91692152	Validation of a Risk Score Incorporating Tumor Characteristics into the American Joint Committee on Cancer Anatomic Stage for Breast Cancer
Q28075719	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation
Q98302968	Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution
Q39022194	Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients.
Q89665021	Variant morphology and random chromosomal integration of BK polyomavirus in posttransplant urothelial carcinomas
Q37595980	Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models
Q37407384	Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Q44521334	Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility
Q48301412	Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET.
Q85281790	We are all individuals... bioinformatics in the personalized medicine era
Q39053758	Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Q92624799	Whole-exome and whole-transcriptome sequencing of canine mammary gland tumors
Q41708245	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples
Q47150037	Worsened outcome in patients with pancreatic ductal carcinoma on long-term diabetes: association with E-cadherin1 (CDH1) promoter methylation
Q39794283	[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Q85484175	[Genomic signature of breast cancer: The quest for the Holy Grail]
Q53073585	[HER2 testing in gastric cancer : Results of a meeting of German experts].
Q57110598	[Metastatic breast cancer in the spine : Molecular predictors for choosing adequate treatment strategies]
Q52868166	[Molecular pathology for breast cancer: Importance of the gene expression profile].
Q35795297	c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer
Q40858674	c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer
Q37707589	mRNA expression of delta-HER2 and its clinicopathological correlation in HER2-overexpressing breast cancer
Q89842473	miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil
Q43595352	p-mTOR expression is associated with better prognosis in luminal breast carcinoma
Q34786457	p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.

P356	DOI	10.1200/JCO.2013.50.9984
P698	PubMed publication ID	24101045

P50	author	Edith A. Perez	Q18389345
		Mitch Dowsett	Q53099690
		Giuseppe Viale	Q80639743
		Gail H. Vance	Q84512726
P2093	author name string	Wedad Hanna
		Daniel F Hayes
		Kimberly H Allison
		Patricia A Spears
		M Elizabeth H Hammond
		David G Hicks
		Michael F Press
		Robert B Jenkins
		Antonio C Wolff
		Donald C Allred
		John M S Bartlett
		Lisa M McShane
		Michael Bilous
		Pamela B Mangu
		Patrick Fitzgibbons
		Soonmyung Paik
		Antonio C. Wolff
		Daniel F. Hayes
		David G. Hicks
		Donald C. Allred
		John M.S. Bartlett
		Kimberly H. Allison
		Lisa M. McShane
		M. Elizabeth H. Hammond
		Michael F. Press
		Pamela B. Mangu
		Patricia A. Spears
		Robert B. Jenkins
P433	issue	31
P407	language of work or name	English	Q1860
P921	main subject	breast cancer	Q128581
		Erb-b2 receptor tyrosine kinase 2	Q415271
P304	page(s)	3997-4013
P577	publication date	2013-11-01
P1433	published in	Journal of Clinical Oncology	Q400292
P1476	title	Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
		Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
P478	volume	31

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

article

Reverse relations